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1. Introduction  
Caregivers treating hospitalized patients are confronted with the necessity both to control 
hyperglycemia and also to avoid iatrogenic hypoglycemia. Despite controversy about 
optimal glycemic targets, a large body of evidence associates uncontrolled hyperglycemia 
with adverse outcomes, both in the intensive care unit and also on general hospital wards 
(American Diabetes Association, 2011; Moghissi et al., 2009). On general wards, glycemic 
control during use of scheduled subcutaneous insulin is superior to that seen during use of 
sliding scale regimens (Baldwin et al., 2005; Umpierrez  et al., 2007). When scheduled insulin 
was compared to sliding scale treatment among general surgical patients, glycemic control 
was improved (mean blood glucose 145 ± 32 mg/dL vs. 172 ± 47 mg/dL, p < 0.01), and a 
composite outcome of complications was reduced from 24.3 to 8.6%with odds ratio 3.39 
(95% CI 1.50-7.65), p = 0.003 (Umpierrez et al., 2011). Nevertheless, the problem of 
hypoglycemia is a barrier to successful control of hospital hyperglycemia. Among 1718 
adult patients admitted at academic medical centers and having hyperglycemia or receiving 
insulin therapy, hypoglycemia occurred on 2.8% of all hospital days (Boord et al., 2009). 
Predisposing factors and adverse outcomes associated with hypoglycemia have been 
examined in observational studies and in clinical trials studying the effect of glycemic 
control upon nonglycemic outcomes (Bagshaw et al., 2009; Fischer et al., 1986; Finfer et al., 
2009;  Kagansky et al., 2003; Krinsley et al., 2007; Maynard et al., 2008; Smith et al., 2005; 
Stagnaro-Green et al., 1995; Turchin et al., 2009; Van den Berghe et al., 2006; Varghese et al., 
2007; Vriesendorp et al., 2006; Wexler et al., 2007). Mortality of patients having myocardial 
infarction is higher at the lowest as well as the highest ranges glucose, such that the 
relationship between mortality and glucose is described by a J-shaped curve (Kosiborod et 
al., 2008). Outcomes of hospitalized patients that have been linked to hypoglycemia include 
increased ICU mortality or hospital mortality rates, adverse events such as seizures, and 
increased length of stay. In the intensive care unit and on general wards, associated factors 
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identified among patients having hypoglycemia include use of bicarbonate-based 
substitution fluid during continuous venovenous hemofiltration, need for inotropic support, 
greater severity of illness, co-administration of octreotide with insulin, comorbidities 
including chronic kidney disease, sepsis, advanced age, history of diabetes or severe 
diabetes, and history of prior episodes of hypoglycemia. Of special importance, because of 
the implication for prevention, is the frequency with which the literature on hospital 
hypoglycemia describes interruption of normal feedings attributable to hospital routine, or 
episodes of reduced enteral intake without adjustment of insulin therapy, as a factors 
predisposing to hypoglycemia.    
Mechanisms of potential harm from hypoglycemia are partially understood, but the causal 
relationships between hypoglycemia or iatrogenic hypoglycemia and outcomes is unclear. 
Concerning the association of hypoglycemia with adverse outcomes, it remains a tenable 
explanation at least in part that severity of illness may predispose both to adverse outcomes 
and to hypoglycemia (Kosiborod et al., 2009;  van den Berghe et al., 2006). Proof of 
permanent injury ascribed to a hypoglycemic episode in the hospital setting sometimes is 
available, but the case ascertainment rate is low. Although proof of direct harm from 
identifiable hypoglycemic events within large studies may be not discerned by statistical 
analysis, yet the harm is uniquely damaging to the individual suffering the hypoglycemic 
event, so that the reporting of isolated cases remains important (Bhatia et al., 2006; Scalea et 
al., 2007). Life-changing morbidity or mortality may result from a severe hypoglycemic 
reaction. It is also suspected that some harms may result from hypoglycemia that are not 
directly traceable to immediate consequences of a specific hypoglycemic event. Since 
hospital patients will not be randomized to hypoglycemia or non-hypoglycemia, our 
understanding of the causes and clinical impact of hypoglycemia will be observational, 
resulting from analyses of hypoglycemia as a secondary outcome, within trials of 
therapeutic strategies or interventions aiming at targets other than hypoglycemia, or 
resulting from analysis of hypoglycemia within cohort studies. For the present, the 
association of hypoglycemia with adverse outcomes justifies development of strategies for 
prevention of hypoglycemia in the hospital.  
The goal of this chapter is to describe attributes of a programming pathway for 
computerized order entry that may incorporate the best elements of paper protocols for 
subcutaneous insulin and that may help prevent hospital hypoglycemia. In designing 
treatment for the hyperglycemic patient, it is necessary to anticipate events that create risk 
for hypoglycemia and to meet those events with appropriate revisions of nutritional therapy 
and scheduled insulin. When insulin orders are in place but patient risk for hypoglycemia is 
predicted to increase, the components of insulin therapy that might be withheld or reduced 
may differ, depending upon co-morbidities, anticipated disruption of carbohydrate 
exposure, alteration of other medical therapies, and classification of diabetes. By juxtaposing 
elements of care within a checklist of orders, paper protocols present reminders to the 
prescriber about strategies for hypoglycemia prevention. We believe the main opportunity 
for improvement within computerized order entry systems is the need to present several 
different packages of orders at the user interface that match differing patterns of 
carbohydrate exposure. For each pattern of carbohydrate exposure, the package must 
include default and acceptable alternative orders that encompass monitoring of blood 
glucose, scheduled and correction-dose insulin orders, and menus of additional directions 
associated with the insulin orders.  
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2. Algorithms for glycemic management in the hospital 
Any algorithm must identify a target blood glucose or a target range and define a safe and 
effective method for attainment and homeostatic maintenance of target range control. 
Provisions must be in place regardless of algorithm design to make anticipatory adjustments 
to prevent hypoglycemia in case of sudden change of any of the usual determinants of 
insulin requirement, such as carbohydrate exposure or concomitant medications. After 
making brief reference to an algorithmic method for protection against hypoglycemia 
during intravenous insulin infusion, the literature on electronic order entry of glycemic 
management plans is briefly referenced, and idealized examples of programmable 
branching pathways for patients who are eating and not eating will be presented. 
2.1 Intravenous insulin infusion 
Computerization of intravenous insulin algorithms may be successfully accomplished either 
through a free standing electronic decision support system or as part of a hospital computer 
system (Dortch et al, 2008;  Hermayer et al. 2007; Junega et al, 2007). The method of 
computerized order entry that we will use is under construction and will not be presented 
here, except to say that the algorithms are related to those previously published (Bellam and 
Braithwaite, 2010; Devi at al, in press 2011). The choice of intravenous insulin protocol 
depends upon the population treated. The protocols will be designed according to a 
mathematical rule having population-specific parameters. The protocols are related to 
column-based tabular protocols in which each column of the table is associated with an 
assumed maintenance rate of insulin infusion that is thought to be the rate necessary to 
maintain target range control. Each row of the table represents a range of blood glucose 
values. The assumed maintenance rate (column assignment) is determined with knowledge 
of the previous assumed maintenance rate (column assignment) together with the rate of 
change of blood glucose, at the previous insulin infusion rate. The next insulin infusion rate, 
at each nursing interaction, depends upon the blood glucose (the row) and the reassigned 
maintenance rate (column re-assignment, if any). The conservative protocol differs from the 
standard critical care protocol for intravenous insulin infusion not in the target range blood 
glucose values, but in the column change rules that result in changing from a lower to a 
higher maintenance rate (column), or from a higher to a lower assumed maintenance rate 
(column). That is to say, by analogy with a paper protocol, the column change rules based 
on rate-of-change of glucose are more conservative under the conservative protocol. We 
believe that two design features of the intravenous insulin infusion protocols will be shown 
to be protective against hypoglycemia, namely (1) the column change rules based on rate of 
change of blood glucose and (2) the near-sigmoidal relationship, at given maintenance rate 
(within-column), between the insulin infusion rate and the blood glucose. 
The protocols for diabetic ketoacidosis and hyperglycemic hyperosmolar state each differ 
from each other and from the critical care protocols for intravenous insulin infusion by 
having different column change rules and additionally different target ranges for blood 
glucose. The target range for blood glucose in treatment of diabetic ketoacidosis or 
hyperglycemia hyperosmolar coma is higher than for other patients likely to be treated with 
intravenous insulin infusion. An initially fixed-dose weight-based method for assigning 
insulin infusion rate during the initial hours of treatment is advocated in the consensus 
statement of the American Diabetes Association for use during the first several hours of 
treatment of DKA (Kitabchi et al., 2009). In contrast, a dynamic rule to assign the insulin 
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infusion rate during treatment of hyperglycemic crisis is employed at our institutions (Devi 
et al., 2011). The deactivation time for intravenous insulin infusion may be as long as 90 
minutes (Mudaliar et al., 2008). A rationale for a dynamic insulin infusion rate in the early 
hours of treatment for hyperglycemic emergency is that under conventional management 
late hypoglycemia sometimes complicates the treatment course.   
2.2 Algorithms for subcutaneous insulin 
Many protocols for hospital care were developed in the era of handwritten order entry. 
Order sets were developed that served as a checklist to prevent omissions of elements of 
care. For example, a reminder to have a standing "prn" order for intravenous dextrose under 
selected conditions or to order an A1C may be part of the order set. Order sets help integrate 
the components of care with each other. Timing of testing, insulin, and meals may be 
coordinated by justaposition of related orders on a paper order set. A lynchpin of successful 
order writing is the coordination of the patterns of glucose monitoring and insulin 
administration with carbohydrate exposure (Bellam and Braithwaite, 2010; Braithwaite et 
al., 2007; Campbell et al., 2004; Thompson et al., 2005). If an order set is well designed, by 
checking boxes and entering numbers the prescriber creates orders that are familiar to and 
readily interpreted by pharmacy and nursing staff. Lengthy narrative is reduced. 
Standardization of order entry protects patient safety. A well designed order set facilitates 
individualization of patient care. Guidelines may be appended to or embedded within order 
sets, together with references to supportive medical literature (Donaldson et al. 2006; 
Hermayer et al, 2009; Lee et al. 2008; Maynard et al., 2009; Schnipper et al., 2010; Trujillo et 
al., 2008; Wexler et al., 2010). Protocols executed through order sets were thought to reduce 
medical errors, improve safety, and increase adherence to those guidelines that were 
supported by medical evidence.  
As electronic order entry began to gain widespread use, a body of descriptive studies 
developed concerning the use of structured order sets for electronic order entry for 
subcutaneous insulin therapy in the hospital. Hermeyer and colleagues described a 
comprehensive program, including a web-based calculator for the intravenous insulin 
protocol (Hermeyer et al., 2009). Maynard and colleagues, in a published study of 
computerized order entry with paper guidelines used on the side, defined time periods 1, 2 
and 3 (TP1, TP2, and TP3) during rolling out of the program. Paper statements of guidelines 
adjunctive to computerized order entry were developed (Lee et al., 2008). The relative risk 
(RR) of an uncontrolled patient-stay was reduced from baseline to 0.91 (CI 0.85-0.96) in TP2, 
and to 0.84 (CI 0.77-0.89) in TP3, with more marked effects in the secondary analysis limited 
to patients with at least 8 point-of-care glucose values (Maynard et al., 2009). The percent of 
patient-days with hypoglycemia was 3.8%, 2.9%, and 2.6% in the 3 time periods, 
representing a RR for hypoglycemic day in TP3:TP1 of 0.68 (CI 0.59-0.78). Similar reductions 
were seen in risk for hypoglycemic patient-stays.  
Evidence from cluster randomized studies supports the use of structured order sets to 
improve glycemic outcomes. Schnipper and colleagues in several stages developed a 
computerized version of their order entry system for glycemic control (Schnipper et al.,  
2009;  Schnipper et al., 2010; Trujillo et al., 2008). In a cluster randomized design of 179 
patients at a single site, two of the four medical services were chosen randomly to receive 
the intervention using a computerized order set built into the proprietary computer at 
Brigham and Women’s Hospital. The mean percent of glucose readings between 60-180 was 
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75% in the intervention group and 71% in the usual care group [adjusted RR 1.36 (1.02-
1.80)]. With the intervention, there were a lower patient-day weighted mean glucose (148 vs 
158, p = 0.04); less use of sliding scale (25% vs 58%, p = 0.01); and no difference in 
hypoglycemia < 40 mg/dL (0.5% vs 0.3%, p = 0.58).   Wexler and colleagues at a single site 
randomized medical teams to availability of an electronic insulin order template versus 
usual insulin ordering. Intervention group patients (n=65) had mean glucose of 195 +/- 66 
mg/dl. Control group patients (n=63) had mean glucose of 224 +/- 57 mg/dl (P=0.004). In 
the intervention group, there was no increase in hypoglycemia (Wexler et al., 2010). 
With electronic order entry, there is a risk that some of the integration between the 
components of care might be lost that had been achievable with paper order sets. Under 
some electronic systems, juxtaposition of related orders is lost. Users might have to navigate 
between screens to complete a package of orders relating to diabetes encompassing such 
necessities as a nutrition plan, point-of-care tests, insulin doses, and a treatment plan for 
hypoglycemia. A plan for continuous enteral tube feedings might be entered on one screen, 
followed by insulin orders on another screen, and finally orders for point-of-care glucose 
monitoring and call parameters on a third screen. Orders that are preselected as the likeliest 
choice, based on absolute rate of utilization, could be programmed as defaults but might be 
misapplied to subgroups through user failure to deselect and replace the order for the 
patient at hand. As an example, if the choice “ACHS” appears at the top of a list of possible 
orders for glucose monitoring as the default (ante cibum and hora somni, before meals and 
at bedtime), then an order for ACHS timing could be accepted by default, rather than timing 
more appropriate to the carbohydrate exposure actually planned for a patient who might 
receive continuous enteral tube feedings. 
3. Programming pathway for glycemic management in the hospital 
In the United States, in coming years hospitals will strive to comply with "meaningful use" 
regulations for electronic health records, described in the Health Information Technology for 
Economic and Clinical Health Act (Blumenthal & Tavenner, 2010). Electronic order entry 
will gradually replace handwriting of orders. Some systems will sharply restrict the use of 
free-text entries, creating necessity for a system that will link orders to preprogrammed 
comments that may be selected by the user. A template similar to that of electronic order 
entry might be used to facilitate communication among caregivers at the time of patient 
transfers and discharge. The remainder of this chapter will describe the design of an 
idealized proposal for a programming pathway for electronic order entry for glycemic 
management of hospitalized patients. 
Within the figures showing the programming pathway, orders that are members of a category 
or subcategory have the same level of indentation. Pre-assignment of a default choice within-
category sometimes is justified either based on frequency of use or medical indications. The 
user may select or deselect an order by clicking on a button associated with an order at the 
user interface. In some cases, selection by a provider of one order results in de-selection of 
another order within the same subcategory or category. In other cases, choices within-category 
or within sub-category are not mutually exclusive;  selection of one order does not result in de-
selection of another order (Figure 1). It is envisioned that the user will move through a 
sequence of those screens within the programming pathway that are determined by having 
made an early commitment to one branch of the algorithm. When the provider is satisfied that 
no modifications are required, the provider enters an electronic signature.  
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Fig. 1. Instructions to programmer. Symbols signify the function of buttons at the user 
interface and define the structure of the program. 
3.1 Programming pathway as checklist 
Just as structured paper order sets for subcutaneous insulin therapy may protect the patient 
from omissions of needed elements of care by presenting a checklist, similarly a checklist of 
reminders for glycemic management may appear within a branching programming 
pathway. For example, the main trunk of the branching pathway may call for elements of 
care that are considered to be potentially universally appropriate, such as a standing "prn" 
order for concentrated intravenous dextrose for treatment of hypoglycemia, a nutrition 
consult, or an A1C (Figure 2). The programming pathway that we will present goes on to 
branch into 8 different treatment plans, each having preventive measures related to 
hypoglycemia that are specific to the components of the treatment plan, embedded as 
checklist options for selection, such as “reduce” orders for basal insulin for type 2 diabetes 
or “hold” parameters for prandial insulin (Figure 3).  
3.2 Individualization facilitated under the programming pathway 
It is necessary to specify precautions against hypoglycemia, but manual entry can be 
burdensome. Under the branches of the pathway, measures for hypoglycemia prevention 
could take different forms depending upon the carbohydrate exposure of the patient, 
including but not limited to the scheduling the monitoring of blood glucose, assignment of 
call parameters at alert levels of glucose, pattern of insulin administration, or use of the 
classification of hyperglycemia or diabetes to determine “hold” parameters for specific 
components of insulin therapy. We believe the ordering of these protective additional 
directions is more likely to occur when a complete menu of options is presented to the 
prescriber than when reliance is placed upon provider initiative and recall. To a large extent, 
manual entry of such safety provisions can be replaced by checking boxes and entering 
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numbers. The programming pathway accommodates the spectrum of reasonable provider 
treatment preferences. By offering a menu of treatment alternatives and additional 
directions to the insulin orders, the programming pathway facilitates individualization of 
care for each patient.  
 
 
Fig. 2. Opening screen.  
3.3 Intravenous insulin algorithm selection under the pathway 
The programming pathway specifies options for four different intravenous insulin infusion 
protocols. A full discussion of these pathways is beyond the scope of the present discussion. 
For critical care patients requiring an intravenous insulin infusion, to help the user decide 
whether to order the conservative critical care intravenous insulin infusion protocol or the 
standard one, the user may find a link to a drop-down guideline for indications for the 
conservative IV insulin protocol. This states that the conservative IV insulin protocol will be 
appropriate for patients with renal failure, malnutrition, hepatic failure, sepsis, severe 
congestive heart failure, adrenal insufficiency, and other conditions that the caregiver judges 
to create high-risk for hypoglycemia. The conservative protocol also is the protocol to which 
the prescriber might default, in case a patient already has demonstrated hypoglycemia 
while on the standard protocol but still requires intravenous insulin infusion therapy 
(Figure 3).  
An American Diabetes Association consensus statement provides a summary of diagnostic 
criteria for diabetic ketoacidosis or hyperosmolar hyperglycemic state (Kitabchi et al., 2009). 
The criteria for each can be summarized in a link to a drop-down guideline for diagnosis, 
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accessed from the opening menu (Figure 3). Classification as diabetic ketoacidosis (DKA) is 
suggested by plasma glucose > 250 mg/dL, arterial pH < 7.3, bicarbonate < 15, anion gap > 
12 meq/L, and moderate ketonuria or ketonemia. Classification as hyperglycemic 
hyperosmolar state (HHS) is suggested by plasma glucose > 600 mg/dl, serum osmolality > 
320 mosm/L, arterial pH > 7.3, bicarbonate > 15 meq/L, and minimal ketonuria and 
ketonemia.  
3.4 Subcutaneous insulin algorithm selection under the pathway 
For patients who will receive subcutaneous insulin, once the pattern of carbohydrate 
exposure is determined, then the prescriber can select the appropriate branch of the 
pathway (Figure 3). Selection of a single branch from the list will launch an appropriate 
submenu, dependent upon carbohydrate exposure, for the schedule of blood glucose 
monitoring and the selection and timing of components of insulin administration. One 
branch of the programming pathway presently under construction will provide for a 
diabetes hospital patient self-management program. Models for patient self-management in 
the hospital have been described (Braithwaite et al., 2007; Bailon et al., 2009). The focus of 
this chapter is on orders for subcutaneous insulin therapy for patients who are not 
candidates for hospital self-management.  
 
 
Fig. 3. Selection of branch of the pathway. 
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3.5 Subcutaneous insulin dose titration after pathway initiation  
A method for establishing starting doses of insulin is described in sections that will follow. 
An associated guideline might state that rewriting of the doses of scheduled insulin should 
be considered daily. Here, a guideline for revision of scheduled insulin is presented that is 
appropriate to each subcutaneous pathway.  
• review comorbidities and medications affecting insulin requirement and carbohydrate 
exposure or omission. 
• review the medication administration record for confirmation of insulin dosing over the 
preceding 24 hr. 
• add the total amount of scheduled and correction dose insulin delivered in the previous 
24 hr to determine total daily dose of insulin actually delivered. 
• if all blood glucose readings were > 180 mg/dL, add 10% to the total daily dose actually 
delivered in the previous 24 hr to determine the new total daily dose of scheduled 
insulin. 
• if any blood glucose was < 80 mg/dL, subtract 20% from the total daily dose actually 
delivered in the previous 24 hr to determine the new total daily dose of scheduled 
insulin. 
The new dose of scheduled insulin is reapportioned between the components of scheduled 
therapy. Once the treatment pattern has been entered, changing of dose or correction dose 
scale can be accomplished outside of the programming pathway. If there are no further 
specifications, any standing "additional directions" concerning scheduled insulin may be 
carried forward.  
Therapeutic inertia in changing established insulin regimens is a recognized problem in the 
care of hospitalized patients. In a study of 52 hospitalized patients treated with 50% 
dextrose for an episode of hypoglycemia, it was found that subsequent to withholding of 
insulin at the time of the hypoglycemia, 31% of the patients received no other change in 
treatment (Garg et al., 2004). The guideline above would give caregivers direction on 
trouble-shooting of the causes of hypoglycemia and making appropriate revisions of 
treatment. 
3.6 Integration of the components of care under the pathway during placement of 
orders for subcutaneous insulin    
A decision support system helps the prescriber to recognize the components of care under 
the pattern of treatment that is ordered and the relationship between these components. 
During widespread adoption of computerization of order entry, a distinct computer order is 
required separately for feedings, intravenous dextrose, glucose monitoring, each component 
of insulin therapy, treatment of hypoglycemia, and call parameters. The relationship of these 
elements of care to each other and their timing must be coordinated. The integration of the 
components of care, achieved by many paper protocols and order sets, must be preserved. 
The prescriber must be able to accomplish the goals of glycemic control and hypoglycemia 
prevention without navigation through multiple screens of an electronic order entry system. 
Whether patients are eating or not, interruption of carbohydrate exposure is a well verified 
risk factor for hospital hypoglycemia. The risk arises from hospital routine that interrupts 
feedings or patient factors that result in poor oral intake  (Fischer et al., 1986). Restrictions 
on free-text entries will necessitate preprogramming of additional directions. In each branch 
of the pathway that will be shown, in case of reduction of carbohydrate exposure, the 
insulin orders may be accompanied by standardized statements concerning hypoglycemia 
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prevention. Examples include additional directions to “hold” prandial insulin in case of 
meal omission, “hold” prandial insulin on the mornings of dialysis, or “reduce” insulin in 
case of poor oral intake.  
The order entry system should associate the pattern of blood glucose monitoring, the 
components of insulin administration together with additional directions, the "call" 
parameters, and the orders for "prn" oral or intravenous carbohydrate. If an order entry 
system is well designed, the user will encounter a comprehensive electronic menu for 
prescribing a glycemic management plan, having internally coordinated components, 
accessible through a single branch of the pathway of order entry. Under each of the first 
three branches of the pathway, nursing instructions include an assessment of patient needs, 
including early attention to patient education and eventual discharge planning.  
3.6.1 Subcutaneous Insulin for patients who are eating   
Basal-prandial-correction therapy is a prescribing pattern for insulin, described in previous 
reviews, that is especially well suited to insulin treatment of the hospitalized patient who is 
eating (Hirsch, 2005; Clement et al., 2004). The orders for monitoring and insulin are written 
in association with a meal plan, usually a consistent carbohydrate diet. Other specifications 
to the diet are preserved that may be required for care of comorbidities. The nursing orders 
for monitoring of blood glucose provide options for testing postprandially but recommend 
restriction of scheduled postprandial testing to conditions in which retrospective review of 
the results might be used to revise scheduled therapy for special populations or conditions, 
such as pregnancy or cystic fibrosis (Figure 4). Most patients require either testing with 
meals; with meals and at bedtime; or with meals, at bedtime, and midsleep.  
Prandial insulin coverage is the treatment given to cover meals, and basal insulin is the 
treatment necessary to prevent unchecked gluconeogenesis and ketogenesis, required 
whether or not nutrition is provided. The long-acting insulin analogs glargine and detemir 
are designed to provide basal coverage. Glargine may be given once daily for most patients, 
and detemir may be given once or twice daily. The rapid-acting insulin analogs lispro, 
aspart and glulisine are designed to provide prandial coverage and to provide rapid 
correction of hyperglycemia. Biphasic or premixed insulin therapy provides both basal and 
prandial insulin coverage. In the hospital, since there is a risk of interruption of meals, it is 
desirable to use an insulin treatment plan under which the prandial component of treatment 
can be interrupted without compromise to the basal insulin coverage. For patients eating 
discrete meals, biphasic insulin therapy in the hospital generally is replaced by treatment 
separately with basal coverage and prandial coverage. For correction of hyperglycemia, the 
rapid-acting insulin analogs are given with meals, sometimes for coverage of snacks, and 
sometimes at bedtime or midsleep.  
Some patients having type 2 diabetes who normally require insulin may experience 
reduction of insulin resistance during fasting and may produce endogenous insulin 
sufficient that under conditions of reduced oral intake the requirements for exogenous 
insulin may decline. Others, who normally are insulin independent, may experience stress-
related insulin resistance in the hospital sufficient to produce a requirement for exogenous 
insulin treatment. Dose initiation guidelines for insulin-requiring patients whose dose 
requirements are not known might be stated conservatively as follows (with 
reapportionment as indicated for special conditions, as described below):  
• daily basal requirement 0.15 units/kg for type 2 diabetes or for stress hyperglycemia, 
and 0.25 units/kg for type 1 diabetes  
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• daily prandial requirement 0.15 units/kg for type 2 diabetes or for stress 
hyperglycemia, and 0.25 units/kg for type 1 diabetes, apportioned between three meals. 
The total daily dose of scheduled insulin is apportioned between the scheduled basal and 
prandial insulin. A guideline concerning the initial percentage distribution of total daily 
dose of scheduled insulin between the components of therapy may suggest 50% basal and 
50% prandial for most patients, but reapportionment for special conditions: 
• 50%  basal insulin, 50%prandial insulin for many patients  
• > 50%  basal insulin, < 50%prandial insulin during immediate recovery following heart 
surgery  




Fig. 4. Nursing orders for patients who are eating. WMEALS = with meals. WMEALS, HS = 
with meals and at bedtime. Times of meals may differ according to institutional practices. 
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Under a treatment plan using basal-prandial-correction dose therapy, typically basal insulin 
is given once daily as long-acting insulin analog. Before development of insulin analogs, 
NPH insulin had been used to provide basal coverage, and regular insulin to provide 
prandial coverage and correction of hyperglycemia. In general, during the treatment of type 
2 diabetes, in comparison with NPH-based basal insulin regimens there is less 
hypoglycemia with use of long-acting insulin analog therapy for basal coverage (Rosenstock 
et al., 2005; Hermansen et al., 2006). However, some patients prefer to be treated with NPH. 
Morning dosing with NPH insulin may provide both basal and partial prandial insulin 
coverage. In the ambulatory setting, some patients use NPH insulin to achieve pattern 
correction; for example, an evening dose of NPH insulin may cover the dawn phenomenon, 
correcting a pattern of morning hyperglycemia by meeting predawn insulin resistance with 
increased insulin levels. Under the branch of the pathway for patients who are eating, 
prescribers are given the alternatives of using a long-acting insulin analog or NPH for basal 
insulin coverage (Figure 5).  
Not uncommonly, in order to correct fasting hyperglycemia, doses of intermediate or long 
acting insulin may have been increased during normal dietary intake to a dose higher than 
true basal requirements. If the basal insulin dose is unchanged during NPO status (nihil per 
os, nothing by mouth), patients having type 2 diabetes may experience hypoglycemia 
(Olson et al., 2009). It is important that the programming pathway should present options 
for basal insulin reduction or interruption in case of planned NPO status. On the other hand, 
if the basal insulin dose is established correctly in type 1 diabetes, the dose during NPO 
status usually may be preserved (Mucha et al., 2004). Omission of basal insulin during NPO 
status in type 1 diabetes may result in ketoacidosis. Therefore, the programming pathway 
provides options for prescribers to reduce basal insulin in type 2 diabetes but to continue 
basal insulin in type 1 diabetes, in anticipation of NPO status. A prescriber guideline 
embedded in the order entry screen warns against interruption of basal insulin for type 1 
diabetes (Figure 5). 
In the treatment of type 2 diabetes, rapid-acting analogs for prandial coverage may produce 
less hypoglycemia than regular insulin (Anderson et al., 1997; Raymann et al, 2006; Velussi 
at al. 2002). The provider may see the need to provide differing doses of prandial insulin at 
different times of day; the programming pathway permits flexibility in the prescribing of 
prandial doses, allowing either a fixed dose (best ordered usually with a consistent 
carbohydrate diet) or a variable dose (Figure 6). This programming pathway is designed for 
use on the assumption that not all nursing staff are trained on recognition of carbohydrate 
content of meals; therefore, insulin-to-carbohydrate ratios are not prescribed under the 
branch of the pathway for subcutaneous insulin for patients who are eating. A modification 
of the pathway might be used by hospitals that routinely train all nurses on advanced 
carbohydrate counting so that the provider might order and nurses might use an insulin to 
carbohydrate ratio to assign prandial insulin doses according to what is on the patient’s 
tray. Patients using the skills of advanced carbohydrate counting and already skilled in self 
management may best be treated under a different branch of the pathway, for diabetes 
hospital patient self management.  
Several additional directions may be selected in conjunction with orders for prandial use of 
rapid-acting insulin analog that provide protection against hypoglycemia. Most obviously, 
the direction “HOLD IF NPO” is intended to reduce the risk of administration of prandial 
insulin at times when meals might be omitted. The order to hold prandial insulin for  
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Fig. 5. Basal insulin orders for patients who are eating. The start time and duration for each 
recurring medication order are to be programmed, but will not shown. SC = 
subcutaneously; NPO = nihil per os (nothing by mouth). Abbreviations may differ 
according to institutional policy. 
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glucose below a given threshold replicates a conservative practice pattern that many users 
of multiple daily insulin injections employ at home. Acceptable control may be achieved by 
postprandial administration of rapid-acting insulin analog (Jungmann, 2005). For patients 
whose oral intake is uncertain, the programming pathway provides the option that the use 
of prandial insulin might be withheld until 50% of the tray has been taken. For patients with 
stage V chronic kidney disease having hemodialysis, there may be greater risk for 
hypoglycemia on hemodialysis days (Kazempour-Ardebili et al., 2009). To permit insulin 
dose reduction by dose omission of rapid-acting analog at breakfast and lunch on dialysis 
days, a checkbox is provided specifying that the nurse should withhold the scheduled rapid-
acting analog before breakfast and lunch on hemodialysis days (Figure 6).  
 
 
Fig. 6. Prandial insulin (nutritional insulin) for patients who are eating. BG = point-of-care 
blood glucose.  
Frequent dosing with rapid-acting analogs for correction of hyperglycemia creates the risk 
of “stacking” of effect. When a patient has had hyperglycemia prior to a meal, consideration 
of another correction dose may arise in the postprandial state. The effect of a previously 
administered correction dose may not have been fully exerted when the blood glucose is 
retested. Use of a fixed glucose-dependent correction dose rule, designed to meet specific 
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pre-meal targets, may result in hypoglycemia when applied postprandially, prior to full 
dissipation of the effects of any earlier correction dose. Therefore, orders for correction doses 
under the programming pathway are restricted to the following three time plans for 
administration:  with meals; HS (bedtime); 0200. The orders may provide a different scale 
for each of those three time plans (Figure 6). 
 
 
Fig. 7. Bridging doses of insulin for patients who are eating, at the time of transition from 
intravenous insulin infusion to subcutaneous insulin. 
Transitioning guidelines from intravenous insulin infusion to subcutaneous insulin 
recommend that the provider should order subcutaneous insulin before interruption of 
insulin infusion (Osburne et al., 2006). Infrequently small amounts of basal and prandial 
insulin (but not subcutaneous correction doses) may be started more than 2 - 4 hr prior to 
interruption of intravenous insulin infusion. In order to transition from intravenous insulin 
to subcutaneous insulin, the 24-hr requirement for scheduled subcutaneous basal insulin 
that is to be started or added may be about 80% of the 24-hr amount of  basal insulin, 
extrapolated from observation of insulin requirement during the last 6-8 hr of intravenous 
insulin infusion. To avoid overestimation of basal dose requirement, observation must be 
made during a timeframe of medical stability during which there have been no meals, such 
as midnight to 0800; there must be no change of carbohydrate-containing maintenance 
fluids, enteral feedings, or total parenteral nutritional at the time of transition to 
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subcutaneous insulin therapy; there must have been independence from pressors and 
continuous veno-venous hemodialysis; and there must be no change of corticosteroid dose. 
If the time of transition occurs at a time of day that differs from the usual time of 
administration of long-acting insulin analog, then a bridging dose of regular or 
intermediate-acting insulin may be given (Figure 7). 
3.6.2 Subcutaneous insulin for patients who are not eating  
The patient receiving continuous exposure to carbohydrate as intravenous dextrose or 
enteral feedings, or the patient receiving no carbohydrate, generally should have glucose 
monitoring at time intervals that are equally spaced (Figure 8). The order “ACHS” for a 
patient who has been made “NPO” is meaningless. Therefore, the branch of the 
programming pathway for patients who are not eating starts with the default order for 
monitoring of point-of-care blood glucose every 6 hr. 
During NPO status, the dose of insulin required to cover dextrose-containing maintenance 
fluids, total parenteral nutrition (TPN), or enteral tube feedings is described as nutritional 
insulin. Outside of the programming pathway, the provider may include insulin among the 
TPN additives. long-acting insulin analog sometimes is used for coverage of continuous 
enteral feedings. Under such a regimen, safety precautions must be in place for dextrose 
infusion in case of interruption of enteral feedings. A barrier to creating a universal rule is 
that patient tolerance for intravenous fluids differs according to condition. Safety data about 
use of basal insulin during enteral feedings, conducted with careful definition of insulin 
dose, has been generated in the context of a clinical trial, such that close supervision of the 
patients can be assumed to have occurred (Koryotkoski et al., 2009).  
Personal observation of isolated cases of severe hypoglycemia outside of the research 
context has led to concern that safety of covering enteral feedings with long-acting analog, 
demonstrated under controlled research conditions, is not generalizable. In actual practice, 
use of long-acting analog to cover enteral feedings can be complicated by protracted 
hypoglycemia, a special risk in case of unforeseen interruption of enteral feedings.  When 
NPH and regular insulin are used every 6 hours, each insulin dose is smaller than under a 
once-daily glargine program, and the frequency of insulin administration provides 
deliberate stacking of effect. The use of more frequent and smaller doses of intermediate 
acting insulin achieves control superior to that of sliding scale insulin; such therapy is 
intended to reduce the risk of prolonged exposure to high doses of long-acting insulin in 
case of sudden interruption of enteral feedings, and to reduce the importance of reliance 
upon the antidote of intravenous dextrose, in case of feeding interruptions.  
A “sliding scale” regimen of NPH insulin every 4 hr or every 6 hr has been examined, 
compared to sliding scale aspart insulin alone for treatment of patients receiving enteral 
feedings (Cook, A. et al., 2009). Amber Cook and colleagues use a standardized rule for 
altering the NPH dose based on response of blood glucose. In our programming pathway, 
and on the antecedent paper order sets, in contrast to the closely related regimen of Amber 
Cook at al., we specify an option for use of mixtures of NPH and regular insulin every 6 
hours. The prescribing style is intended to achieve flat-line coverage of insulin effect. The 
method described in our guideline is to administer equal doses of insulin every 6 hours, 
apportioned as 2/3 NPH and 1/3 regular insulin, with instructions to withhold the regular 
insulin in case of glucose below a given threshold. 
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Fig. 8. Nursing orders and scheduled insulin orders for patients who are not eating, 
including patients receiving continuous dextrose-containing maintenance fluids, continuous 
enteral feedings, or no carbohydrate exposure. 
The algorithm we use does not provide a protocolized rule for changing the NPH dose 
based on glycemic  response, but rather alters insulin delivery below a given glucose 
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threshold by protocolized omission of scheduled regular insulin. The prescriber within the 
programming pathway is invited to provide the additional direction for scheduled regular 
insulin “HOLD FOR BG < XXX” (where BG = point-of-care blood glucose).  
Transitioning guidelines from intravenous insulin infusion to subcutaneous insulin for the 
prescriber include the following, with recognition that the guidelines may not be 
appropriate for every case, and that individualization is required:  
• Order subcutaneous insulin before interruption of insulin infusion. Infrequently small 
amounts of scheduled NPH and regular insulin (but not sliding scale) may be started 
more than 2 - 4 hr prior to interruption of intravenous insulin infusion.  
• Prescribe equal total doses of scheduled insulin every 6 hr, apportioned as 2/3 NPH, 
1/3 regular insulin.  
• In order to transition from intravenous insulin to subcutaneous insulin, the 24-hr 
requirement for scheduled NPH and regular insulin that is to be started or added may 
be about 80% of the 24-hr amount of intravenous insulin, extrapolated from observation 
of insulin requirement during the last 6-8 hr of intravenous insulin infusion. To avoid 
overestimation of dose requirement, observation must be made during a timeframe of 
medical stability; there must be no change of carbohydrate-containing maintenance 
fluids, enteral feedings, or total parenteral nutrition at the time of transition to 
subcutaneous insulin therapy; there must have been independence from pressors and 
CVVHD; and there must be no change of corticosteroid dose. 
A set of dose initiation guidelines is given for insulin-requiring patients whose dose 
requirements are not known. The total daily dose of insulin for coverage of enteral feedings 
or continuous intravenous dextrose exposure may be calculated conservatively as follows: 
• 24 hr basal requirement is 0.15 units/kg for type 2 diabetes or for stress hyperglycemia, 
and 0.25 units/kg for type 1 diabetes.  
• nutritional requirement is 1 unit per 10 gm of carbohydrate per 24 hr, as determined by 
review of maintenance fluid or enteral tube feeding composition and delivery rate. 
• for type 2 diabetes or stress hyperglycemia, during continuous carbohydrate exposure, 
the total daily dose of insulin is the sum of the 24 hr basal and nutritional components of 
therapy. 
• the total daily dose of insulin is apportioned between NPH and regular insulin as above. 
On a periodic basis, the caregiver then may alter the scheduled NPH and insulin by revising 
the scheduled insulin orders, using a guideline as shown above for re-establishing total 
daily dose (see section 3.5), and reapportioning the dose between NPH and regular insulin. 
To prevent inadvertent interruption of basal insulin for type 1 diabetes patients who are not 
eating, a special provision is available, in the branch of the programming pathway for 
patients who are not eating, to maintain basal dose requirements of long-acting insulin 
analog treatment when interruption of carbohydrate exposure necessitates interruption of 
nutritional insulin (Figure 9). 
3.6.3 Subcutaneous insulin for patients with overnight enteral feedings and daytime 
meals  
For patients whose oral intake is temporarily poor but likely to improve, overnight enteral 
tube feedings may be used during transition from negligible oral intake to a full meal plan. 
Premixed 70% human insulin isophane suspension/30% human insulin (70/30 NPH / 
regular insulin) may be used as premedication to cover overnight enteral feedings (Figure 
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10). The need for correction dose insulin is likely to occur during and at the end of each 
feeding. As the patient’s intake of oral feedings improves, correction dose insulin during the 
day may be required. For patients having type 1 diabetes, additionally daily use of long 
acting insulin analog should be ordered, in an amount restricted to the basal dose, together 
with the regimen of premixed insulin that is being used for nutritional coverage and regular 
insulin for correction dose coverage. Once dietary intake is adequate, overnight enteral 
feedings and the accompanying premedication with 70/30 isophane NPH/regular insulin 
no longer are required. Once the patient is eating, a new basal-prandial-correction insulin 
regimen may be required.  
3.6.4 Diabetes hospital patient self management  
In the ambulatory setting, skilled use of a flexible insulin program may reduce the 
frequency of hypoglyemia (Samann et al., 2006). Patients competent at diabetes self-
management, for example patients using multiple daily injections or insulin pump therapy, 
under defined conditions can be treated in the hospital with continuation of their usual 
program of self-management (Braithwaite et al., 2007;  Bailon  et al., 2009). A full description 
of such a program is beyond the scope of this chapter. A hallmark feature is the utilization 
of the skills of advanced carbohydrate counting to permit matching of mealtime insulin 
bolus doses to carbohydrate intake, and the use of a rule for establishment of correction 
doses for treatment of hyperglycemia. 
 
 
Fig. 9. Basal insulin orders for type 1 diabetes patients who are not eating. 
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Fig. 10. Insulin orders for patients having overnight enteral tube feedings and daytime meals. 
4. Conclusion 
A programming pathway for computerized order entry is described that will present 
templates to the prescriber for well-established strategies for control of hyperglycemia and 
prevention of hospital hypoglycemia. There is not yet an embodiment of the plan within an 
existing electronic health record, nor is the content specifically yet endorsed by the 
healthcare system of the authors, but rather the plan is proposed in general terms as a 
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springboard for development and for modification to meet local needs. A user of the 
electronic order entry system may opt out of the programming pathway. The pathway is 
intended to both standardize order entry and also to facilitate individualization of care by 
the provider and for the patient. An opening screen offers default orders that will be 
universally desirable for glycemic management and then asks the user to choose a branch of 
the programming pathway based on route of insulin (intravenous or subcutaneous) and, for 
subcutaneous insulin regimens, based upon carbohydrate exposure. Within each branch of 
the pathway for subcutaneous insulin, it is possible to complete related orders without 
navigation between screens and without use of free-text, by entering numbers and selecting 
additional directions from side menus and drop down menus. User guidelines are displayed 
or available by computer link. By grouping and prioritizing related orders (especially the 
plans for nutrition, glucose monitoring, and insulin) and by offering appropriate additional 
directions within a branch of the pathway, the integration of the components of care, 
achievable on paper order sets by juxtaposition, is preserved under the electronic order 
entry system by user choice of a branch of the programming pathway. 
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